Scarica l'app Stockscreener
37.24
3.60%
-1.39
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$38.63
Aprire:
$38.71
Volume 24 ore:
1.70M
Relative Volume:
1.09
Capitalizzazione di mercato:
$2.00B
Reddito:
-
Utile/perdita netta:
$-38.99M
Rapporto P/E:
-12.43
EPS:
-2.9966
Flusso di cassa netto:
$-24.94M
1 W Prestazione:
-10.33%
1M Prestazione:
-10.29%
6M Prestazione:
-54.10%
1 anno Prestazione:
-27.45%
Intervallo 1D:
$36.89
$39.79
Intervallo di 1 settimana:
$36.89
$41.84
Portata 52W:
$36.89
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Nome
Soleno Therapeutics Inc
Settore
Industria
Telefono
650-213-8444
Indirizzo
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
37.24 | 2.07B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-10-07 | Iniziato | Goldman | Buy |
| 2025-08-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-23 | Iniziato | TD Cowen | Buy |
| 2025-03-05 | Ripresa | Stifel | Buy |
| 2024-12-02 | Reiterato | Robert W. Baird | Outperform |
| 2024-12-02 | Reiterato | Stifel | Buy |
| 2024-09-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-10 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-05 | Iniziato | Piper Sandler | Overweight |
| 2024-01-23 | Iniziato | Stifel | Buy |
| 2023-11-21 | Ripresa | Guggenheim | Buy |
| 2020-09-29 | Iniziato | Guggenheim | Buy |
| 2020-01-10 | Iniziato | Craig Hallum | Buy |
| 2019-12-23 | Iniziato | Oppenheimer | Outperform |
| 2018-02-13 | Reiterato | Maxim Group | Buy |
Mostra tutto
Soleno Therapeutics Inc Borsa (SLNO) Ultime notizie
Soleno Therapeutics stock hits 52-week low at 37.95 USD By Investing.com - Investing.com Australia
Soleno Therapeutics (NASDAQ:SLNO) Sets New 1-Year LowTime to Sell? - MarketBeat
Is Soleno Therapeutics Inc. currently under institutional pressure2025 Key Lessons & Intraday High Probability Alerts - mfd.ru
SLNO: Strong market uptake, stable safety, and robust reimbursement support ongoing growth - TradingView
Why is Soleno Therapeutics Inc. stock going downGap Up & Safe Entry Trade Reports - mfd.ru
Soleno Therapeutics stock hits 52-week low at 37.95 USD - Investing.com
Why Soleno Therapeutics Inc. (6XC) stock is listed among top recommendationsJuly 2025 Reactions & Weekly Watchlist for Hot Stocks - mfd.ru
Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET - The Manila Times
Rare disease biotech Soleno sets Feb. 25 call on 2025 results - Stock Titan
Soleno Therapeutics prices $200M public offering - MSN
Soleno Therapeutics (SLNO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Eastern Progress
Pullback Watch: Why is Soleno Therapeutics Inc. stock going downMarket Growth Report & Fast Moving Market Watchlists - baoquankhu1.vn
Why a biotech is drawing attention to a rare disease at the Super Bowl - Medical Marketing and Media
Soleno Therapeutics (NASDAQ:SLNO) Lowered to "Hold" Rating by Zacks Research - MarketBeat
(SLNO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
What Soleno Therapeutics (SLNO)'s VYKAT XR Momentum and 2025 Outlook Could Mean For Shareholders - Sahm
VYKAT XR Launch Momentum Could Be A Game Changer For Soleno Therapeutics (SLNO) - Yahoo Finance
A Look At Soleno Therapeutics (SLNO) Valuation As VYKAT XR Launch Shapes A “Transformational” 2025 - Yahoo Finance
A Look At Soleno Therapeutics (SLNO) Valuation After VYKAT XR Launch And Upcoming 2025 Business Updates - Sahm
Published on: 2026-02-03 13:03:09 - baoquankhu1.vn
Down 18.3% in 4 weeks, here's why Soleno Therapeutics (SLNO) looks ripe for a turnaround - MSN
Soleno Therapeutics (NASDAQ:SLNO) Stock Price Up 8.3%Time to Buy? - MarketBeat
Soleno Therapeutics stock jumps nearly 9% today — what SLNO traders are watching next - TechStock²
Down 18.3% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround - Yahoo Finance
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Compelling 190% Upside Potential - DirectorsTalk Interviews
Universal Beteiligungs und Servicegesellschaft mbH Sells 32,627 Shares of Soleno Therapeutics, Inc. $SLNO - MarketBeat
Risk Hedge: Is Diebold Nixdorf Incorporated a good ESG investmentRate Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Sell Signal: Will Soleno Therapeutics Inc outperform the market in YEAR2025 Key Highlights & Verified Swing Trading Watchlist - baoquankhu1.vn
Soleno Therapeutics stock hits 52-week low at 39.42 USD By Investing.com - Investing.com South Africa
Soleno Therapeutics Shares Dip Following $200 Million Stock Offering Pricing - MSN
Soleno Therapeutics (NASDAQ:SLNO) Hits New 52-Week LowShould You Sell? - MarketBeat
Soleno Therapeutics stock hits 52-week low at 39.42 USD - Investing.com
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - MSN
Soleno Therapeutics to Participate in Upcoming Conferences - The Manila Times
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC) and Soleno Therapeutics (SLNO) - The Globe and Mail
Solena Therapeutics (SLNO) Stock Under Pressure But Upside is Huge - Finviz
Soleno Therapeutics (SLNO) Stock Analysis: Unveiling a Potential 164% Upside in the Biotech Arena - DirectorsTalk Interviews
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Liquidity Mapping Around (SLNO) Price Events - Stock Traders Daily
Soleno Therapeutics Updates Executive Compensation and Severance Plans - The Globe and Mail
Is Soleno Therapeutics, Inc. (NASDAQ:SLNO) The Best Under $50 Stock to Buy Now? - Insider Monkey
Emerald Mutual Fund Advisers Trust Reduces Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics Inc. (SLNO): Analysts See Major Upside - Finviz
Soleno Therapeutics (SLNO) Valuation Checked After New Q4 2025 Revenue Guidance - Sahm
FY2025 Earnings Estimate for SLNO Issued By HC Wainwright - MarketBeat
Emerald Advisers LLC Trims Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
SLNO INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Soleno Therapeutics, Inc. - ACCESS Newswire
Q2 EPS Estimate for Soleno Therapeutics Increased by Analyst - MarketBeat
Soleno Therapeutics stock price target raised to $120 from $110 at H.C. Wainwright - Investing.com Nigeria
Soleno Therapeutics stock price target raised to $120 from $110 at H.C. Wainwright By Investing.com - Investing.com South Africa
Soleno Therapeutics Inc Azioni (SLNO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):